semaglutide and epilepsy Linked to Lower Risk in Type 2 Diabetes semaglutide and seizures Seizure Recurrence

Clinical trials show average weight loss of 15 to 17 percent of body weight with semaglutide

[82] The trial reported cumulative occurrence of major adverse cardiovascular events, a primary end-point event of the trial, for 569 of the 8803 patients in the semaglutide group, which were 6.5% of the participants, and for 701 of the 8801 patients in the placebo group, which were 8% of the participants, showing relative 18.8% less major adverse cardiovascular events, such as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurring for participants who had received semaglutide in the trial relative to those who had received placebo over the course of around 48 months, or 34.213.7 months, which was the mean (SD) total duration of the participants in either group's exposure to the placebo or semaglutide during the trial

Semaglutide vs liraglutide for non-diabetics Even for people without diabetes, improving fasting insulin and post-meal blood sugar early is one of the most powerful ways to prevent future metabolic disease

Marketing vs

Dulaglutide is an option when eGFR is above 15 mL/min/1.73 m, but adjustments may be necessary for severe impairment